Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
PAVM 
PAVmed Inc (PAVM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: PAVM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -60.86% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 11.88M USD | Price to earnings Ratio 1.44 | 1Y Target Price 9 |
Price to earnings Ratio 1.44 | 1Y Target Price 9 | ||
Volume (30-day avg) 148401 | Beta 1.19 | 52 Weeks Range 0.57 - 2.43 | Updated Date 04/1/2025 |
52 Weeks Range 0.57 - 2.43 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.5 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-03-24 | When After Market | Estimate -0.4 | Actual -0.19 |
Profitability
Profit Margin 1328.58% | Operating Margin (TTM) -51870% |
Management Effectiveness
Return on Assets (TTM) -87.19% | Return on Equity (TTM) -1358.06% |
Valuation
Trailing PE 1.44 | Forward PE - | Enterprise Value 45868868 | Price to Sales(TTM) 3.97 |
Enterprise Value 45868868 | Price to Sales(TTM) 3.97 | ||
Enterprise Value to Revenue 15.32 | Enterprise Value to EBITDA -0.33 | Shares Outstanding 16462700 | Shares Floating 12741800 |
Shares Outstanding 16462700 | Shares Floating 12741800 | ||
Percent Insiders 23.32 | Percent Institutions 6.37 |
Analyst Ratings
Rating 4 | Target Price 9 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
PAVmed Inc
Company Overview
History and Background
PAVmed Inc. was founded in 2015 and is a medical device company focused on developing and commercializing minimally invasive medical technologies. It evolved through acquisitions and internal development of innovative medical solutions.
Core Business Areas
- Minimally Invasive Devices: PAVmed develops and commercializes minimally invasive medical devices targeting unmet clinical needs across various medical specialties.
- Veris Health: Digital health subsidiary focused on remote patient monitoring and data analytics in chronic diseases.
- CarpX: Minimally invasive device for carpal tunnel syndrome.
- PortIO: Implantable intraosseous vascular access device
Leadership and Structure
Lishan Aklog, M.D. is the Chairman and CEO. The organizational structure includes various departments such as R&D, clinical, regulatory, sales, and marketing.
Top Products and Market Share
Key Offerings
- CarpX: CarpX is a minimally invasive device for carpal tunnel syndrome release. Market share is emerging. Competitors include traditional open surgery and endoscopic carpal tunnel release techniques. Initial commercialization is underway but revenue contribution is still small.
- revenue: 0
- users: 0
- PortIO: PortIO is an implantable intraosseous vascular access device (IOVAD) designed for patients requiring long-term vascular access. Market share is nascent as it is still in development and initial stages of market penetration. Competitors include PICC lines and central venous catheters. Initial commercialization is underway but revenue contribution is still small.
- revenue: 0
- users: 0
- Veris Health RPM System: Remote patient monitoring system for medication adherence and chronic disease management. The market is growing with increased adoption of telehealth. Competitors include Teladoc Health and other remote patient monitoring solutions. Initial commercialization is underway but revenue contribution is still small.
- revenue: 0
- users: 0
Market Dynamics
Industry Overview
The medical device industry is characterized by innovation, regulatory oversight, and competition. There is a trend towards minimally invasive procedures and remote patient monitoring.
Positioning
PAVmed Inc. is positioned as an innovator in minimally invasive medical technologies. Its competitive advantage lies in its patented technologies and focus on addressing unmet clinical needs.
Total Addressable Market (TAM)
The TAM for PAVmed's products is estimated to be in the billions of dollars across its target markets. PAVmed aims to capture a significant portion of this market through its innovative products and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Innovative technology portfolio
- Strong intellectual property position
- Experienced management team
- Focus on unmet clinical needs
Weaknesses
- Limited financial resources
- Dependence on regulatory approvals
- Commercialization challenges
- Small size relative to competitors
Opportunities
- Expanding market for minimally invasive procedures
- Growing demand for remote patient monitoring
- Strategic partnerships and acquisitions
- New product development
Threats
- Competition from larger medical device companies
- Regulatory changes
- Reimbursement challenges
- Product liability risks
Competitors and Market Share
Key Competitors
- MDT
- BSX
- ABT
- TDOC
Competitive Landscape
PAVmed faces competition from larger, more established medical device companies with greater financial resources and broader product portfolios. PAVmed's competitive advantage lies in its innovative technologies and focus on niche markets.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by new product development and clinical trials, but revenue growth is still limited.
Future Projections: Future growth is projected to be driven by commercialization of CarpX, PortIO, and Veris Health.
Recent Initiatives: Recent strategic initiatives include expanding the sales force, securing regulatory approvals, and establishing strategic partnerships.
Summary
PAVmed is a developing stage medical device company with innovative technology but faces challenges in commercialization and funding. It shows promise with its products, but requires successful market penetration. PAVmed needs to carefully manage its cash flow and navigate regulatory hurdles to achieve long-term success. It should focus on strategic partnerships to expand its reach and compete effectively.
Similar Companies
- MDT
- BSX
- ABT
- TDOC
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About PAVmed Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2016-04-28 | Chairman & CEO Dr. Lishan Aklog M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 39 | Website https://www.pavmed.com |
Full time employees 39 | Website https://www.pavmed.com | ||
PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.